Patrik Jeanmonod's Insider Trades & SAST Disclosures
Patrik Jeanmonod's most recent trade in Cytek BioSciences Inc was a trade of 4,908 Common Stock done . Disclosure was reported to the exchange on March 11, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Patrik Jeanmonod.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Patrik Jeanmonod | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 4,908 | 99,377 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 4,908 | 44,182 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.22 per share. | 11 Mar 2024 | 1,912 | 97,465 | - | 7.2 | 13,805 | Common Stock |
| Cytek BioSciences Inc | Jeanmonod Patrik | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 1,752 | 13,442 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jeanmonod Patrik | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 1,752 | 95,152 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jeanmonod Patrik | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.38 per share. | 20 Feb 2024 | 683 | 94,469 | - | 8.4 | 5,724 | Common Stock |
| Cytek BioSciences Inc | Jeanmonod Patrik | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.50 per share. | 26 Dec 2023 | 3,000 | 93,400 | - | 9.5 | 28,500 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.69 per share. | 24 Aug 2023 | 3,000 | 102,084 | - | 7.7 | 23,070 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 3,681 | 52,771 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 3,681 | 106,518 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 1,752 | 16,946 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 1,752 | 103,520 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 1,434 | 105,084 | - | 8.5 | 12,132 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 683 | 102,837 | - | 8.5 | 5,778 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.17 per share. | 24 Jul 2023 | 3,000 | 101,768 | - | 9.2 | 27,510 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 24 May 2023 | 3,000 | 107,768 | - | 7.8 | 23,280 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 2,454 | 56,452 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 2,454 | 111,724 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,752 | 109,953 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,752 | 18,698 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 956 | 110,768 | - | 6.7 | 6,396 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 683 | 109,270 | - | 6.7 | 4,569 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 24 Apr 2023 | 3,000 | 108,201 | - | 10.2 | 30,720 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.33 per share. | 24 Mar 2023 | 3,000 | 111,201 | - | 8.3 | 24,990 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 89,031 | 89,031 | - | - | Employee Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 58,906 | 58,906 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.05 per share. | 24 Feb 2023 | 3,000 | 114,201 | - | 11.1 | 33,150 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,752 | 117,884 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,752 | 20,450 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 21 Feb 2023 | 683 | 117,201 | - | 11.0 | 7,493 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.05 per share. | 24 Jan 2023 | 3,500 | 76,132 | - | 11.1 | 38,675 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.77 per share. | 27 Dec 2022 | 3,500 | 79,632 | - | 9.8 | 34,195 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.30 per share. | 25 Nov 2022 | 3,500 | 83,132 | - | 14.3 | 50,050 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 1,752 | 22,202 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 1,752 | 87,315 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.75 per share. | 18 Nov 2022 | 683 | 86,632 | - | 14.7 | 10,074 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.16 per share. | 24 Oct 2022 | 3,500 | 85,563 | - | 15.2 | 53,060 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 26 Sep 2022 | 3,500 | 89,063 | - | 12.6 | 44,205 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 08 Sep 2022 | 40,000 | 116,132 | - | 0.4 | 16,000 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2022 | 40,000 | 202,661 | - | - | Employee Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.45 per share. | 24 Aug 2022 | 3,500 | 92,563 | - | 13.5 | 47,075 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 01 Aug 2022 | 3,500 | 94,994 | - | 12.8 | 44,800 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 2,336 | 25,706 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 2,336 | 98,333 | - | - | Common Stock | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.65 per share. | 18 May 2022 | 910 | 97,423 | - | 9.7 | 8,782 | Common Stock |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 42,310 | 42,310 | - | - | Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 28,042 | 28,042 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Patrik Jeanmonod | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges